{"log_id": 1657242287296778995, "direction": 0, "words_result_num": 48, "words_result": [{"probability": {"variance": 0.013233, "average": 0.948117, "min": 0.690897}, "location": {"width": 112, "top": 205, "height": 28, "left": 155}, "words": "【药物过量】"}, {"probability": {"variance": 0.000529, "average": 0.986355, "min": 0.92638}, "location": {"width": 187, "top": 240, "height": 35, "left": 187}, "words": "尚无药物过量的报道"}, {"probability": {"variance": 0.010767, "average": 0.956617, "min": 0.483022}, "location": {"width": 778, "top": 254, "height": 62, "left": 187}, "words": "单次给约耐受试验提示本品在剂量过大时可导致心动过缓,应予以关注(参见不良反"}, {"probability": {"variance": 0, "average": 0.996799, "min": 0.996799}, "location": {"width": 24, "top": 331, "height": 24, "left": 156}, "words": "应"}, {"probability": {"variance": 0.000202, "average": 0.992574, "min": 0.960899}, "location": {"width": 113, "top": 366, "height": 26, "left": 161}, "words": "【临床试验】"}, {"probability": {"variance": 0.021691, "average": 0.939395, "min": 0.446917}, "location": {"width": 773, "top": 373, "height": 61, "left": 197}, "words": "Ⅱ期临床研究采用多中心、随机、双盲、多剂平行对照的研究方法:共入组首次发病"}, {"probability": {"variance": 0.015512, "average": 0.950533, "min": 0.356809}, "location": {"width": 811, "top": 414, "height": 65, "left": 160}, "words": "4小时内的颈内动脉系统脑梗受试者199例,结果显示2次/日,25mg次剂量组疗效与其它"}, {"probability": {"variance": 0.005685, "average": 0.963755, "min": 0.75386}, "location": {"width": 189, "top": 483, "height": 35, "left": 160}, "words": "剂量组相比具有优势"}, {"probability": {"variance": 0.018128, "average": 0.948679, "min": 0.377898}, "location": {"width": 770, "top": 497, "height": 57, "left": 204}, "words": "I期临床研究采用多中心、随机、双育双模拟、阳性药对照研究。共入组首次发病48"}, {"probability": {"variance": 0.002986, "average": 0.975258, "min": 0.725117}, "location": {"width": 814, "top": 533, "height": 64, "left": 165}, "words": "小时以内的颈内动脉系统脑梗死受试者( NIHSS6-25分)552例,其中丁苯酞氯化钠注射液"}, {"probability": {"variance": 0.011378, "average": 0.959784, "min": 0.594361}, "location": {"width": 353, "top": 593, "height": 43, "left": 164}, "words": "组370例,奥扎格雷钠注射液组182例"}, {"probability": {"variance": 0.000201, "average": 0.988586, "min": 0.965611}, "location": {"width": 168, "top": 641, "height": 30, "left": 206}, "words": "全分析集(FAS集"}, {"probability": {"variance": 0.000111, "average": 0.992652, "min": 0.962571}, "location": {"width": 162, "top": 631, "height": 32, "left": 426}, "words": "552)统计分析结果"}, {"probability": {"variance": 0.014771, "average": 0.938657, "min": 0.582359}, "location": {"width": 549, "top": 665, "height": 49, "left": 210}, "words": "丁苯酞氯化钠注射液组在治疗第8大、第15天 NIHSS总评分"}, {"probability": {"variance": 0.008078, "average": 0.962627, "min": 0.516759}, "location": {"width": 514, "top": 708, "height": 49, "left": 169}, "words": "B总评分(54.70)±25.50、63.78±27.06)与治疗前 NIHSS"}, {"probability": {"variance": 0.011048, "average": 0.94917, "min": 0.638895}, "location": {"width": 111, "top": 704, "height": 21, "left": 817}, "words": "B1(45.27±2"}, {"probability": {"variance": 0.004362, "average": 0.96021, "min": 0.771903}, "location": {"width": 301, "top": 756, "height": 41, "left": 172}, "words": "相比,差异均有统计学意义(P<"}, {"probability": {"variance": 0.015293, "average": 0.95328, "min": 0.416559}, "location": {"width": 770, "top": 774, "height": 60, "left": 216}, "words": "与治疗前比较,丁苯氯化钠注射液组治疗后第15天 NIHSS总评分的下降值为"}, {"probability": {"variance": 0.016778, "average": 0.95196, "min": 0.478288}, "location": {"width": 389, "top": 833, "height": 44, "left": 174}, "words": "365±3.29,奥扎格雷钠注射液对照组为3.25"}, {"probability": {"variance": 0.004852, "average": 0.962983, "min": 0.774326}, "location": {"width": 249, "top": 820, "height": 36, "left": 621}, "words": "组间比较差异有统计学意义"}, {"probability": {"variance": 0.013541, "average": 0.948304, "min": 0.502827}, "location": {"width": 779, "top": 855, "height": 66, "left": 179}, "words": "苯酞氯化钠注射液组治疗前后NISS变化率(总评分差值治疗前总评分"}, {"probability": {"variance": 0.017575, "average": 0.931109, "min": 0.442446}, "location": {"width": 760, "top": 896, "height": 65, "left": 179}, "words": "44.540.9%,奥扎格雷钠注射液组为41.24±34.22%,组间比较差异无统计学意义"}, {"probability": {"variance": 0.001652, "average": 0.98126, "min": 0.785717}, "location": {"width": 814, "top": 935, "height": 65, "left": 179}, "words": "0088)。以治疗前的 NIHSS总评分为协变量,治疗前后两组 NIHSS总评分变化值的协方差"}, {"probability": {"variance": 0.005559, "average": 0.975348, "min": 0.644172}, "location": {"width": 446, "top": 993, "height": 46, "left": 181}, "words": "分析结果显示,治疗后第15天差异有统计学意义"}, {"probability": {"variance": 0.047543, "average": 0.841722, "min": 0.533361}, "location": {"width": 25, "top": 994, "height": 18, "left": 697}, "words": "035"}, {"probability": {"variance": 0.002714, "average": 0.974889, "min": 0.796551}, "location": {"width": 778, "top": 1011, "height": 74, "left": 221}, "words": "与治疗前比较,丁苯氯化钠注射液试验组治疗后第15天BI总评分的增加值为"}, {"probability": {"variance": 0.00769, "average": 0.953949, "min": 0.670176}, "location": {"width": 403, "top": 1074, "height": 46, "left": 188}, "words": "8.51±20.44,奥扎格借钠注射液对照组为1"}, {"probability": {"variance": 0.001062, "average": 0.968671, "min": 0.913837}, "location": {"width": 36, "top": 1077, "height": 18, "left": 636}, "words": "8.10"}, {"probability": {"variance": 0.024341, "average": 0.898053, "min": 0.497001}, "location": {"width": 250, "top": 1061, "height": 34, "left": 716}, "words": "组间比较差异无统计学意义"}, {"probability": {"variance": 0.000122, "average": 0.981281, "min": 0.965722}, "location": {"width": 31, "top": 1136, "height": 18, "left": 210}, "words": "0.0"}, {"probability": {"variance": 0.025985, "average": 0.929247, "min": 0.375398}, "location": {"width": 707, "top": 1099, "height": 56, "left": 292}, "words": "J苯氯化钠注射液试验组治疗前后BI变化率(总评分差值/治疗前总评分)为"}, {"probability": {"variance": 0.015286, "average": 0.944382, "min": 0.41083}, "location": {"width": 779, "top": 1140, "height": 58, "left": 191}, "words": "5.12±70.21%,奥扎格雷钠注射液对照为43.85±58.37%,组间比较差异有统计学意义"}, {"probability": {"variance": 0.000483, "average": 0.920416, "min": 0.898434}, "location": {"width": 30, "top": 1217, "height": 16, "left": 195}, "words": "0)"}, {"probability": {"variance": 0.020135, "average": 0.941289, "min": 0.434682}, "location": {"width": 703, "top": 1178, "height": 56, "left": 298}, "words": "以治疗前的BI总评分为协变,疗前后两B总评分变化值的协分"}, {"probability": {"variance": 0.026645, "average": 0.939905, "min": 0.391633}, "location": {"width": 407, "top": 1234, "height": 48, "left": 190}, "words": "结果显示,治疗后第15大异无统计学意义"}, {"probability": {"variance": 3.1e-05, "average": 0.994776, "min": 0.983318}, "location": {"width": 338, "top": 1277, "height": 42, "left": 232}, "words": "符合方案集(PPS集)统计分析结果"}, {"probability": {"variance": 0.023781, "average": 0.932626, "min": 0.406657}, "location": {"width": 533, "top": 1310, "height": 47, "left": 237}, "words": "J苯氯化钠注射液组324例,奥扎格注射液组165例"}, {"probability": {"variance": 0.001194, "average": 0.980145, "min": 0.911168}, "location": {"width": 59, "top": 1355, "height": 20, "left": 685}, "words": "9.90%"}, {"probability": {"variance": 0.05388, "average": 0.577717, "min": 0.36025}, "location": {"width": 62, "top": 1338, "height": 27, "left": 948}, "words": "组为"}, {"probability": {"variance": 0.005858, "average": 0.978572, "min": 0.64722}, "location": {"width": 445, "top": 1355, "height": 45, "left": 197}, "words": "氯化钠注射液试验组治疗前后 NIHSS变化率为49"}, {"probability": {"variance": 0.018431, "average": 0.908551, "min": 0.522522}, "location": {"width": 389, "top": 1396, "height": 45, "left": 200}, "words": "44.83.54%,组间比较差异有统计学义"}, {"probability": {"variance": 0.022964, "average": 0.890774, "min": 0.461437}, "location": {"width": 390, "top": 1377, "height": 48, "left": 663}, "words": "4)其他的统计结论与FA茶"}, {"probability": {"variance": 0.019746, "average": 0.919526, "min": 0.492791}, "location": {"width": 659, "top": 1426, "height": 53, "left": 200}, "words": "集结论一致。在治疗后15天,丁术氯化钠注射液试验组治疗前后BI差"}, {"probability": {"variance": 0.005292, "average": 0.973561, "min": 0.677733}, "location": {"width": 328, "top": 1478, "height": 42, "left": 201}, "words": "总评分一治疗前总评分)为20.42±2"}, {"probability": {"variance": 0.011646, "average": 0.947861, "min": 0.646024}, "location": {"width": 276, "top": 1460, "height": 47, "left": 578}, "words": "奥扎格雷钠注射液对照17"}, {"probability": {"variance": 0.070378, "average": 0.605987, "min": 0.387199}, "location": {"width": 137, "top": 1434, "height": 63, "left": 916}, "words": "3比"}, {"probability": {"variance": 0.001421, "average": 0.976317, "min": 0.871573}, "location": {"width": 252, "top": 1523, "height": 37, "left": 205}, "words": "较差异有统计学意义(P=0"}, {"probability": {"variance": 0.00012, "average": 0.994185, "min": 0.949593}, "location": {"width": 397, "top": 1505, "height": 41, "left": 529}, "words": "其他各项指标的统计结论与FAS集结论一致"}], "language": 3}